Comparative Pharmacology
Head-to-head clinical analysis: ONA MAST versus ONAPGO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ONA MAST versus ONAPGO.
ONA-MAST vs ONAPGO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ONA-MAST (onabotulinumtoxinA) is a neurotoxin that cleaves SNAP-25, a protein required for acetylcholine release at the neuromuscular junction, thereby inhibiting muscle contraction. It also inhibits release of nociceptive neurotransmitters such as substance P and glutamate from sensory neurons, contributing to analgesic effects.
ONAPGO is a fusion protein consisting of a human IgG1 Fc domain linked to the extracellular domain of the activin receptor type IIB (ActRIIB). It acts as a ligand trap for members of the TGF-β superfamily, particularly myostatin and activin, inhibiting their binding to native receptors. This leads to increased muscle mass and bone density.
10-30 mg subcutaneously once weekly
20 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life 4.5 hours; clinically significant for q6h dosing to maintain therapeutic levels.
Terminal elimination half-life is 14 hours; clinically, steady-state is achieved after approximately 3 days of regular dosing.
Renal (approximately 60% as unchanged drug) and biliary/fecal (approximately 30% as metabolites); 10% excreted via sweat/saliva.
Renal excretion of unchanged drug accounts for approximately 80% of elimination, with biliary/fecal excretion accounting for the remaining 20%.
Category C
Category C
Botulinum Toxin
Botulinum Toxin